(NASDAQ: CLDX) Celldex Therapeutics's forecast annual revenue growth rate of 81.1% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.57%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.38%.
Celldex Therapeutics's revenue in 2025 is $7,559,000.On average, 5 Wall Street analysts forecast CLDX's revenue for 2025 to be $245,592,297, with the lowest CLDX revenue forecast at $46,143,997, and the highest CLDX revenue forecast at $644,024,138. On average, 2 Wall Street analysts forecast CLDX's revenue for 2026 to be $517,875,080, with the lowest CLDX revenue forecast at $239,019,268, and the highest CLDX revenue forecast at $796,730,892.
In 2027, CLDX is forecast to generate $3,313,006,232 in revenue, with the lowest revenue forecast at $1,752,807,962 and the highest revenue forecast at $5,869,250,904.